Most research studies have and continue to be studied on predominantly white men. Even within animal studies, researchers have primarily used male animals. As of 1993, the FDA has recommended, though has not required that women are included in clinical trials. For example, there is evidence that women metabolize medications differently than men in several cases. There is also very limited information regarding the effects of menstrual cycles, menopause or pregnancy on medication metabolism. 

Women and racial minorities continue to be underrepresented in clinical trials, which can often lead to an increased risk of side effects, limited efficacy and many other issues.

Preliminary research has shown that there are gender differences and racial differences in reaction to and recovery from COVID.

We petition the FDA to require that any clinical trials relating to COVID-19 increase female and racial minority participation, provide transparency on the percentage of women and racial minority participants, and provide an analysis that may explain any gender or racial differences in the results.

Gender data and race data on participants in clinical trials will allow the public to make more informed decisions for their healthcare.